Navigation Links
The Leukemia & Lymphoma Society: Accelerating Cures Must Be a Priority

WHITE PLAINS, N.Y., April 1, 2011 /PRNewswire/ -- Once again, the Annual Report to the Nation on the Status of Cancer shows a continued decline in diagnoses and deaths for many types of cancers. This encouraging news can be attributed primarily to preventive measures such as cessation of smoking and improved diet, and early detection.


But for many cancers, such as the blood cancers, early detection is rare, there are no measures that can be taken to prevent the onset of the disease, and they are still killing too many. In these cases, the only solution is continued research to find better treatments and cures once the diagnosis is made.

It is for this reason that many voluntary disease organizations have created programs to accelerate therapies from laboratories to patients. We recognize that funding research is costly and difficult, particularly in these trying economic times, particularly for orphan diseases such as blood cancers where producing these treatments may not always be cost-effective for drug companies.

We have to be more proactive and innovative in our approaches to funding drug development, not only funding laboratory research, but also partnering with biotechnology companies on high-prospect research projects, or by providing much needed expertise to help academics bring their discoveries to market.  We are continually searching for new ways to ensure that scientific discoveries are not stuck collecting dust on academic shelves, but are given the boost they need to cross the chasm that swallows so many promising findings.

The Federal government also recognizes this need to get more treatments to patients faster.  A key provision of the federal Affordable Care Act that has received little attention is the creation by Congress of the Cures Acceleration Network (CAN). This program, which would be administered by Frances Collins, Ph.D., director of the National Institutes of Health, would authorize grants to patient advocacy organizations, universities, biotechnology companies, research institutions or pharmaceutical companies, and would also provide the expert guidance necessary to move those discoveries forward.

The potential for these public-private partnerships to succeed is great, but only if there is real funding behind it. Congress is weighing drastic cuts to cancer research funding that would jeopardize this and other critical programs. Nonprofit organizations such as The Leukemia & Lymphoma Society, Cystic Fibrosis Foundation, Multiple Myeloma Research Foundation and Michael J. Fox Foundation have seen these partnerships bear fruit. If Congress gets on board and funds this program, there is no doubt that more lives will be saved.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.  

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif

SOURCE The Leukemia & Lymphoma Society
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
2. Alfacells ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells
3. In 2008, Ipsogen Reinforced its Leadership in Molecular Diagnosis and Monitoring of Leukemia
4. International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"
5. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
6. Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting
7. Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma
8. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
9. The Leukemia & Lymphoma Society and The International Waldenstroms Macroglobulinemia Foundation Partner to Develop Cell Lines to Advance Research
10. Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
11. Childrens Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman ... AngelList early in their initial angel funding process. Now, they are paying it ... to make early stage investments in the microbiome space. In this, they ...
(Date:11/24/2015)... VANCOUVER , Nov. 24, 2015 /CNW/ - iCo ... ICOTF), today reported financial results for the quarter ... are expressed in Canadian dollars and presented under ... the United States ," said Andrew ... "These advancements regarding iCo-008 are not only value ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)...  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General ... a.m. Israel time, at the law offices of ... 36 th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election ... , approval of an amendment to certain terms of options granted to ...
Breaking Biology Technology:
(Date:11/19/2015)... , Nov. 19, 2015  Based on its in-depth ... Sullivan recognizes BIO-key with the 2015 Global Frost & ... Frost & Sullivan presents this award to the company ... to the needs of the market it serves. The ... meets and expands on customer base demands, the overall ...
(Date:11/17/2015)... Paris from 17 th until 19 ... from 17 th until 19 th November 2015. ... invented the first combined scanner in the world which scans ... now two different scanners were required: one for passports and ... the same surface. This innovation is an ideal solution for ...
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
Breaking Biology News(10 mins):